Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs-Reference-Cited by-同舟云学术

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR ‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs

Published:2020-10-19 Issue:12 Volume:11 Page:3501-3509
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Yang Lu¹^ORCID,Hao Xuezhi¹,Hu Xingsheng¹,Wang Zhijie¹,Yang Ke²,Mi Yuling³,Yang Yaning¹,Xu Haiyan⁴^ORCID,Yang Guangjian¹,Wang Yan¹^ORCID

Affiliation:

1. Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. Department of Medical Oncology Cancer Hospital of Huanxing Chaoyang District Beijing Beijing China

3. Department of Medical Oncology Chaoyang Sanhuan Cancer Hospital Beijing China

4. Department of Comprehensive Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13689

Reference39 articles.

1. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts

2. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

3. Lung Cancer in China

4. EGFR mutation incidence in non‐small‐cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII);Midha A;Am J Cancer Res,2015

5. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure;Oncology Letters;2024-08-20

2. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

3. Understanding and Targeting the Epigenetic Regulation to Overcome EGFR-TKIs Resistance in Human Cancer;Recent Patents on Anti-Cancer Drug Discovery;2023-11

4. Hope and Challenges: Immunotherapy in EGFR-Mutant NSCLC Patients;Biomedicines;2023-10-28

5. Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies;Chinese Medical Journal;2023-06-27